Form 8-K - Current report

false000113872300011387232025-01-212025-01-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 21, 2025

ACCURAY INCORPORATED

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-33301	20-8370041
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1240 Deming Way
Madison, Wisconsin				53717-1954
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 608 824-2800

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ARAY		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

---

 

Item 7.01. Regulation FD Disclosure.

 

On January 21, 2025 Accuray Incorporated (the “Company”) issued a press release regarding the hiring of Leonel Peralta as the Company’s Senior Vice President, Chief Operations Officer, effective February 3, 2025. A copy of this press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Item 7.01 disclosure, including Exhibit 99.1, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated January 21, 2025, titled “Leonel Peralta to Join Accuray as Chief Operations Officer”

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

2

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACCURAY INCORPORATED
Dated: January 21, 2025	By:	/s/ Jesse Chew
		Jesse Chew
		Senior Vice President, Chief Legal Officer & Corporate Secretary

 

 

 

3

---

EXHIBIT 99.1

 

 

Leonel Peralta to Join Accuray as Chief Operations Officer

 

MADISON, Wis., January 21, 2025 – Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter.

 

Mr. Peralta has a proven work history in driving growth while improving productivity and bringing more than 25 years of leadership experience in supply chain, business process improvement, and manufacturing optimization. Most recently, Leonel was Vice President, Head of Global Operations for the ultrasound division at Siemens Healthineers where he led the transformation of supply chain processes, the manufacturing footprint and the organizational structure, for the ultrasound business unit within the company. Prior to this, Leonel held executive management positions at Medtronic Diabetes, Hill-Rom (Baxter), KCI Medical (3M), and GE Healthcare. Under his leadership his teams executed corporate growth and financial objectives, significantly reduced inventory levels, and transformed sourcing and supply chain operations.

 

“On behalf of the entire Accuray organization I welcome Leonel to the team. He is joining Accuray at an important juncture in the company’s business and I look forward to the impact he will make in enhancing our global operations. Over the past year we have expanded our radiation therapy system portfolio and Leonel’s broad expertise will be instrumental in driving business growth while simultaneously driving operational efficiencies and ensuring world class customer satisfaction,” said Suzanne Winter, President and CEO of Accuray.

 

"I am deeply honored to be joining Accuray, a company dedicated to extending the lives of cancer patients worldwide through innovation and an unwavering passion to combat one of the world’s toughest diseases,” said Leonel Peralta. “It will be a privilege to lead a team that exemplifies operational excellence and is committed to making the company’s transformative technology accessible to everyone, everywhere."

 

About Accuray

Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

 

###

 

Media Contact

Beth Kaplan

Accuray

[phone]

---

EXHIBIT 99.1

[e-mail]

 

Investor Contact

Aman Patel, CFA

Investor Relations, ICR-Westwicke

[phone]

[e-mail]

 

---

Document And Entity Information	Jan. 21, 2025
Cover [Abstract]
Entity Registrant Name	ACCURAY INCORPORATED
Amendment Flag	false
Entity Central Index Key	0001138723
Document Type	8-K
Document Period End Date	Jan. 21, 2025
Entity Incorporation, State or Country Code	DE
Entity File Number	001-33301
Entity Tax Identification Number	20-8370041
Entity Address, Address Line One	1240 Deming Way
Entity Address, City or Town	Madison
Entity Address, State or Province	WI
Entity Address, Postal Zip Code	53717-1954
City Area Code	608
Local Phone Number	824-2800
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ARAY
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

---